Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730996 | 0.95 | KCNH2 (0.32) | LRRK2GRM5KCNH2ENPP3ALPL | |
| SCHEMBL4105032 | 0.88 | LRRK2 (0.37) | LRRK2GRM5KCNH2MAT2ACYP1A2 | |
| SCHEMBL4109832 | 0.84 | ENPP3 (0.39) | LRRK2MAT2AENPP3ALPLENPP1 | |
| SCHEMBL4109187 | 0.80 | ENPP3 (0.50) | KCNH2ENPP3ALPLENPP1XIAP | |
| SCHEMBL4748718 | 0.78 | PKM (0.35) | LRRK2KCNH2CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL4115341 | 0.77 | RAPGEF4 (0.33) | LRRK2KCNH2CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL4751023 | 0.74 | KCNH2 (0.37) | LRRK2KCNH2CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL4751664 | 0.73 | RAPGEF4 (0.33) | KCNH2CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL4105432 | 0.73 | AR (0.38) | LRRK2MAT2A | |
| SCHEMBL4103776 | 0.72 | PKM (0.34) | LRRK2CYP1A2CYP2C19SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111856-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096950-A1 | Compounds Useful In Therapy | CYP19A1, LPXN, HSD17B11 | LRRK2 4414/4885GRM5 3344/4885KCNH2 1777/4885 |
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | LRRK2 3396/4885GRM5 2550/4885KCNH2 984/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | LRRK2 3140/4885GRM5 2945/4885KCNH2 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.